SIHUAN PHARM: XuanZhu Bio's innovative drug DaluoAke tablets approved for market launch

Zhitong
2025.08.22 12:09

SIHUAN PHARM announced that its subsidiary XuanZhu Bio's self-developed ALK inhibitor class 1 innovative drug Dirocitinib tablets have been approved for marketing by the National Medical Products Administration of China for the treatment of advanced non-small cell lung cancer with anaplastic lymphoma kinase positivity. Dirocitinib has four core advantages, including rapid onset, excellent tumor suppression intensity, durable relief, and significant survival benefits. According to data from ZhiShi Consulting, in 2024, there will be 91,200 ALK-positive NSCLC patients in China, expected to reach 121,700 by 2032, with a compound annual growth rate of 3.7%; in 2024, the market size for ALK inhibitors in China is approximately 4.7 billion yuan, forecasted to increase to 8.9 billion yuan by 2032, with a compound annual growth rate of 8.3%

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.